Alto neuroscience reports topline results from a phase 2b trial evaluating alto-100 as a treatment for major depressive disorder

Mountain view, calif.--(business wire)--alto neuroscience, inc. (“alto”) (nyse: anro), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the phase 2b study of alto-100 in patients with major depressive disorder (mdd) did not meet its primary endpoint, assessed by a change from baseline in montgomery-Åsberg depression rating scale (madrs), compared to placebo. the favorable safety and tolerabili.
ALTO Ratings Summary
ALTO Quant Ranking